GlassScriptPhysician profile
Joseph Venturini
NPI 1588002364
$30,786.59
in general payments reported to CMS, 2019-2025
29 companies · $2,673 in 2025
The $2,673 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,869 · 2021: $646 · 2022: $3,288 · 2023: $4,884 · 2024: $3,298 · 2025: $2,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,556 · Travel and Lodging: $4,956 · Entertainment: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,556.30 |
| Travel and Lodging | $4,955.58 |
| Entertainment | $343.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $14,593.15 | 2019-2020 | |
| Edwards Lifesciences Corporation | $4,629.30 | 2019-2025 | Pascal, Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $2,915.27 | 2019-2025 | Amplatzer Amulet, Triclip, Mitraclip |
| Ancora Heart, INC. | $2,618.68 | 2022-2025 | Accucinch |
| Abiomed | $1,474.29 | 2021-2025 | Impella |
| Medtronic, INC. | $1,284.74 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $805.00 | 2021-2025 | Watchman Access System, Avvigo Guidance System, Synergy |
| Cardiva Medical, INC. | $469.61 | 2020-2025 | Savvywire, Optowire, Other |
| Opsens INC. | $363.43 | 2023 | Optowire |
| Philips North America LLC | $270.84 | 2022-2024 | (Ao0) Igt Devices Intracardiac |
| Livanova USA, INC. | $200.49 | 2021-2023 | Tandemlife, Lifesparc |
| Biotronik INC. | $124.00 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $116.78 | 2025 | Opsumit, Uptravi |
| Terumo Medical Corporation | $107.09 | 2021-2023 | Glidewire |
| Penumbra, INC. | $103.85 | 2023 | Smart Coil |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $101.42 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Teleflex LLC | $101.33 | 2023-2025 | Turnpike, Trapliner, Arrow |
| Lantheus Medical Imaging, INC. | $97.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $95.20 | 2019-2020 | |
| Amgen INC. | $69.45 | 2019-2024 | Repatha |
| Pfizer INC. | $61.38 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $37.97 | 2025 | Optimizer |
| Cordis US Corp. | $31.00 | 2022-2023 | Wizdom (Stylized) |
| Regeneron Healthcare Solutions, INC. | $28.62 | 2019 | |
| Inari Medical, INC. | $27.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Heartflow, INC. | $24.99 | 2025 | |
| Angiodynamics, INC. | $15.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.72 | 2020 | |
| Cardiovascular Systems INC. | $5.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Venturini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.